China's API sales up 22 pct in first eight months
Shanghai. October 22. INTERFAX-CHINA - China's active pharmaceutical ingredients (API) factories achieved a total sales revenue of RMB 146.96 billion ($22.00 billion) in the first eight months of 2010, up 22.46 percent year-on-year, according to an Oct. 20 report on the Ministry of Commerce's (MOFCOM) Web site.
In terms of sales revenue, private API manufacturers achieved the fastest rate of growth in the eight-month period at 27.78 percent year-on-year. State-owned API manufacturers, meanwhile, saw a 24.05 percent increase in revenue over the pervious year, while foreign-backed manufacturers clocked an increase of 22 percent over last year.
State-owned manufacturers also saw their profits increase, up 46.06 percent year-on-year, while private manufacturers witnessed an increase of 39.02 percent and foreign-backed manufacturers 18.82 percent.
Sales revenue from API manufacturers based in the provinces of Shandong, Zhejiang, Jiangsu and Hebei accounted for 54.77 percent of China's total.
Figures from the China Chamber of Commerce for Import and Export of Medicines and Health Products showed API exports in the January to August period were valued at $13.45 billion, an increase of 28.54 percent year-on-year. API export prices in August were 10.43 percent higher than those in July, the figures show.